What is Acylanid used for?

Acylanid is indicated for Atrial fibrillation, Congestive heart failure.

Acylanid is developed by Novartis.

What development phase is Acylanid in?

Acylanid is FDA-approved (marketed).

What is the generic name of Acylanid?

ACETYLDIGITOXIN is the generic (nonproprietary) name of Acylanid.

Last reviewed 2026-04-20 · How we verify

Acylanid (ACETYLDIGITOXIN)

Novartis · FDA-approved approved Small molecule Quality 30/100

Acetyldigitoxin, also known as Acylanid, is a small molecule drug developed by Novartis that targets the sodium/potassium-transporting ATPase. It is used to treat atrial fibrillation and congestive heart failure. The drug is off-patent, meaning it is no longer protected by patents, and there are no generic manufacturers. Acetyldigitoxin was approved by the FDA in 1975 and has a bioavailability of 70%. As an off-patent drug, its commercial status is uncertain.

At a glance

Generic name	ACETYLDIGITOXIN
Sponsor	Novartis
Drug class	acetyldigitoxin
Target	Sodium/potassium-transporting ATPase
Modality	Small molecule
Therapeutic area	Metabolic
Phase	FDA-approved
First approval	1975

Approved indications

Atrial fibrillation
Congestive heart failure

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Acylanid CI brief — competitive landscape report
Acylanid updates RSS · CI watch RSS
Novartis portfolio CI